Contact Me | QA VALIDATION ENGINEER CONSULTANT (UK)

Select Page

Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements May 17, 2019
Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing May 17, 2019

Class 2 Medicines Recall: Co-amoxiclav 125 mg/31.25 mg/5 ml and 25 mg/62.5 mg/5 ml Powder for Oral Suspension (MDR 24-05/19) May 13, 2019
Class 4 Medicines Defect Information: Prednisolone 5mg Tablets (MDR 61-04/19) April 26, 2019